fig2
![Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases](https://image.oaes.cc/a94ce938-174e-41d4-8eb5-000aa30c0064/2988.fig.2.jpg)
Figure 2. Body weight and MDA-MB231(SA) tumor burden. Whole body tumor burden was analyzed by fluorescence imaging. A: Representative images showing established metastatic foci before treatment (day 14) and at sacrifice (day 25); B: body weight during the study relative to body weight at the day of tumor cell inoculation. Significant differences in body weight at sacrifice relative to baseline were not observed; C: whole body tumor burden did not differ between the groups as measured by fluorescent imaging. Data are expressed as mean ± SD, n = 8 animals. Scale bars 10 mm, arrows tumor foci in vivo. NS: non-significant; DOX: doxorubicin; ZOL: zoledronic acid